Macular Degeneration Clinical Trials
Dry Age-Related Macular Degeneration
Anti-Inflammation
Apellis OAKS
Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration.
Learn more.
Genentech (GALLEGO)
A study assessing the safety, tolerability, and efficacy of RO7171009 in participants with geographic atrophy secondary to dry age-related macular degeneration (GALLEGO).
Learn more.
Ophthotech
Zimura (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration.
Learn more.
Boehringer Ingelheim Pharmaceuticals
Safety, tolerability, and pharmacokinetics of single doses BI 425809.
Learn more.
University of Virginia TOGA
Clinical study to evaluate treatment with ORACEA® (oral doxycycline) for geographic atrophy (TOGA).
Learn more.
For more information about
Retina Clinical Trials,
call 215-928-3444
Cell Based
Astellas (AIRM)
A Phase 1b dose escalation evaluation of safety and tolerability and a Phase 2 proof of concept investigation of efficacy and safety of ASP7317 for atrophy secondary to dry age-related macular degeneration.
Learn more.
Lineage/Cellcure*
Safety and efficacy study of OpRegen for treatment of advanced dry age-related macular degeneration.
Learn more.
*pending
Genetic Screening
MedSpace (Gyroscope Therapeutics)
To evaluate the natural progression of dry age-related macular degeneration.
Learn more.
Gemini Therapeutics
A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with non-central geographic atrophy (GA) who are carriers of high-risk genetic complement variants associated with dry age-related macular degeneration (AMD).